From the perspective of growth drivers, overseas expansion has become an important development direction for enterprises. 2020 Driven by public health prevention and control in 2022, China's A-share medical device-related enterprises ushered in important opportunities for overseas development, and the scale of overseas revenue increased rapidly from 25.7 billion yuan in 2018 to 108.1 billion yuan in 2022, with a compound annual growth rate of 432%, and the proportion of overseas revenue increased from 22% to 341%。Xingye ** believes that in 2024, medical devices going overseas may be as hot as innovative drugs going overseas in 2020.
In the context of the continuous deepening of medical reform and the continuous acceleration of aging, it is recommended to pay attention to the relevant directions of pharmaceutical "going to sea" and "out-of-hospital", the former mainly includes innovative drugs and devices, especially equipment and consumables companies with faster innovation iteration.
Medical Device Index ETF (159898) passively tracks the CSI All-Index Medical Device Index, as an important medical segment, medical devices have obvious characteristics of high threshold, high barriers and ** value, and the long-term performance of the secondary market is more prominent. As of January 26, 2024, since the base day of December 31, 2004, the CSI All-Index Medical Device Index has risen by 953%, equivalent to an annualized return of 1354%。